糖尿病患者血清可溶性细胞间粘附分子-1和可溶性血管细胞粘附分子-1变化的研究

目的　研究糖尿病患者血清可溶性细胞间粘附分子 - 1(s ICAM- 1)和可溶性血管细胞粘附分子 - 1(s VCAM- 1)水平的变化。方法　应用酶联免疫吸附法 (EL ISA)检测了 18例 1型糖尿病和 47例 2型糖尿病患者及 2 0例健康对照者的血清 s ICAM- 1、s VCAM- 1以及甘油三酯 (TG)水平。结果　 1血清 s ICAM- 1和 s VCAM- 1水平 ,1型、2型糖尿病患者组均显著高于健康对照组 (P<0 .0 5～ 0 .0 1) ,2型糖尿病有微血管病变组又高于无微血管病变组 (P<0 .0 5～ 0 .0 1) ,1型糖尿病与 2型糖尿病组之间无显著性差异 ;2血清 s VCAM- 1水平 ,2型糖尿病的高甘油三酯血症组 (A组 )、高甘油三酯血症合并高血压组 (B组 )高于单纯高血压组 (C组 )和甘油三酯、血压正常组 (D组 ) (P均 <0 .0 5 ) ;3 1型糖尿病和 2型糖尿病患者血清 s ICAM- 1和 s VCAM- 1之间均呈正相关关系 (r=0 .83、0 .5 3,P均 <0 .0 1)。结论　 12型糖尿病患者血清 s VCAM- 1升高与高甘油三酯血症有关 ;2血清 s ICAM- 1和 s VCAM- 1参与了糖尿病微血管病变的发病过程 ,并可作为糖尿病病情变化的监测指标     

2型糖尿病患者血清C反应蛋白与可溶性细胞粘附分子水平变化的临床意义

目的　探讨 2型糖尿病患者血清 C反应蛋白 (CRP)、可溶性细胞粘附分子水平变化及其与血管并发症的关系。方法　采用 EL ISA法检测 12 7例 2型糖尿病患者 (糖尿病组 )血清 CRP、可溶性血管细胞间粘附分子 - 1(s VCAM- 1)和可溶性细胞间粘附分子 - 1(s ICAM- 1)水平 ,并与 6 4例健康人 (对照组 )进行比较。结果　糖尿病组血清 CRP、s ICAM- 1、s VCAM- 1均明显高于对照组 ,有极显著性差异 (P <0 .0 1) ;有血管并发症者CRP、s ICAM- 1、s VCAM- 1明显高于无血管并发症者 (P<0 .0 1) ,大血管并发症、微血管并发症和大血管与微血管并发症并存者各指标比较差异均有显著性 (P <0 .0 1)。糖尿病组血清 CRP水平与 s ICAM- 1、s VCAM- 1水平变化呈正相关 (r =0 .5 76～ 0 .6 2 4 ,P <0 .0 1)。结论　血清 CRP、 s ICAM- 1、 s VCAM- 1相互作用、可能参与了糖尿病的发生与发展 ,并与血管并发症的发生与发展有密切关系     

高脂血症患者粘附分子水平及调脂干预的研究

目的　观察高脂血症患者可溶性 P-选择素 ( s P- sel)和可溶性细胞间粘附分子 - 1( s ICAM- 1)的表达及阿托伐他汀的调脂干预的作用。方法　用酶联免疫吸附法 ( EL ISA)及放免法检测 32例高脂血症患者 (男 19例 ,女 13例 )服用阿托伐他汀 ( 10 mg/ d,疗程 4～ 6周 )前后血浆 s ICAM- 1和 s P- sel的水平并与性别、年龄相匹配的 30例正常血脂组对照。结果　高脂血症患者血浆 s ICAM- 1和 s P- sel的水平明显高于对照组 ( P<0 .0 1) ;阿托伐他汀治疗 4～ 6周后总胆固醇 ( TC)、甘油三酯 ( TG)、低密度脂蛋白胆固醇 ( L DL - C)、s ICAM- 1和 s P- sel的水平显著下降 ( P<0 .0 1) ;s ICAM- 1和 s P- sel与 TC、L DL- C、TG呈正相关 ( P<0 .0 5 ) ,HDL- C升高不明显。结论　 1)血浆 s ICAM- 1和s P- sel的表达增加推测是高脂血症致动脉粥样硬化的一个重要环节 ;2 )阿托伐他汀降低 s ICAM- 1和 s P- sel水平可能主要是通过调节血脂而产生。     

卡维地洛对不稳定型心绞痛患者血清细胞因子和心肌缺血的影响

目的：探讨卡维地洛对不稳定型心绞痛患者血清细胞因子和心肌缺血的影响。方法：选择100例不稳定型心绞痛患者,分为卡维地洛组和常规治疗对照组（各50例）,测定治疗前后可溶性细胞间粘附分子-1（sICAM-1）和可溶性P-选择素（P-selectin）水平,并观察两组患者治疗前后心肌缺血指标的变化。结果：卡维地洛组和常规治疗对照组患者治疗6个月后血清sICAM-1和可溶性P-选择素水平较治疗前明显降低（P〈0．01,〈0．05）,其中卡维地洛组患者血清sICAM-1和可溶性P-选择素水平降低较对照组更为明显（P均〈0．05）。卡维地洛组和常规治疗对照组患者心绞痛持续时间缩短,ST段下移减轻（P〈0．01,〈0．05）,但卡维地洛组疗效更加明显（P〈0．05）;卡维地洛组的临床疗效总有效率94％,优于常规治疗对照组的72％（P〈0．05）。结论：卡维地洛可以降低不稳定型心绞痛患者血清sICAM-1和可溶性P-选择素水平,抑制冠脉粥样病变的炎症反应,改善心肌缺血症状,是治疗不稳定型心绞痛的理想药物。     

老年颈动脉硬化患者血清黏附分子的研究

目的 研究老年患者血清内皮细胞黏附分子(ICAM-1)、血管细胞黏附分子-1(VCAM-1)、E选择素和P选择素等黏附分子水平与颈动脉硬化的关系.方法 收集176例老年颈动脉硬化患者,采用酶联免疫吸附法测定血清ICAM-1、VCAM-1、E选择素和P选择素水平;对患者作颈动脉超声检查并按动脉硬化的程度分组,比较不同程度颈动脉硬化患者血清黏附分子水平变化.结果 颈动脉增厚和颈动脉斑块组患者血清ICAM-1、VCAM-1、E选择素和P水平均显著高于对照组,颈动脉斑块组血清ICAM-1和P选择素水平均较颈动脉增厚组显著升高(P＜0.05).颈动脉硬化程度与血清黏附分子水平呈显著正相关(P＜0.05).结论 老年患者外周血中黏附分子水平在一定程度上反映患者的颈动脉硬化程度.     

血清可溶性P-选择素水平与急性脑梗死的相关性研究

目的探讨急性脑梗死患者血清可溶性P-选择素水平的变化及其临床意义。方法选择急性脑梗死患者120例,根据病情分为首发组64例,复发组56例,同时选取同期门诊体检的健康者72例为对照组,比较各组间血清可溶性P-选择素水平,并分析其与脑梗死的相关性。结果首发组和复发组血清可溶性P-选择素高于对照组,且复发组高于首发组。单因素相关分析显示,可溶性P-选择素与超敏C反应蛋白（hsCRP）、纤维蛋白原（Fib）、血压、血小板分布宽度（PDW）、血小板平均体积（MPV）、梗死体积及人院时神经功能评分呈正相关,与HDL—C、PLT呈负相关。多因素非条件Logistic回归分析显示,脑梗死与可溶性P-选择素、hsCRP呈正相关。结论血清可溶性P-选择素水平升高可能是脑梗死独立的危险因素。     

老年类风湿关节炎患者血清MMP-13、sICAM-1、IL-10的检测

目的探讨老年类风湿关节炎患者血清基质金属蛋白酶(MMP)-13、可溶性细胞黏附分子(s ICAM)-1和白细胞介素(IL)-10检测的临床意义。方法选择2013年9月至2014年9月来该院治疗的类风湿关节炎老年患者48例为观察组,同期选择48例健康人员作为对照组。观察两组人员血清MMP-13、s ICAM-1、IL-10的情况。结果观察组血清MMP-13、s ICAM-1、IL-10水平高于对照组(P<0.01或P<0.05)。类风湿关节炎患者活动期组也均高于对照组和缓解期组(P<0.01或P<0.05)。类风湿关节炎患者MMP-13、s ICAM-1、IL-10水平与血沉(ESR)、高敏C-反应蛋白(hsCRP)呈显著正相关(P<0.05),与病程相关性较小(P>0.05)。结论血清MMP-13、s ICAM-1、IL-10水平与类风湿关节炎的发病及病情进展有关,可作为类风湿关节病情判断的指标,具有较高的临床应用价值。     

血清可溶性细胞间粘附分子-1和E-选择素水平与冠心病的关系

目的比较冠心病(CHD)患者血清可溶性细胞间粘附分子-1(sICAM-1)和血清可溶性E-选择素水平,探讨其临床意义.方法 145例冠心病患者,其中73例为急性冠脉综合征组(ACS组),72例为稳定型冠心病组(SCHD组),并选144名健康查体者作对照组.用酶联免疫吸附法(ELISA)检测血清sICAM-1、可溶性E-选择素水平,并比较上述指标水平在三组之间的差异.结果血清sICAM-1浓度ACS组(320.3±81.8)μg/L和SCHD组(266.5±63.5)μg/L明显高于对照组(176.3±78.3)μg/L,P<0.01,ACS组和SCHD组间也有显著性差异(P<0.05).血清可溶性E-选择素浓度ACS组(48.5±12.1)μg/L和SCHD组 (36.1±11.9)μg/L明显高于对照组(28.8±10.3)μg/L,P<0.01,ACS组和SCHD组间也有显著性差异(P<0.05).结论血清sICAM-1、可溶性E-选择素在冠心病患者中明显高于对照组,其中ACS患者明显高于SCHD患者.     

慢性充血性心力衰竭患者血清sICAM-1与血管紧张素Ⅱ相关性研究

目的　研究慢性充血性心力衰竭 (CHF)患者血清可溶性细胞间粘附分子 - 1(s ICAM- 1)和血管紧张素 (Ang )的变化 ,并探讨两者之间的关系。方法　分别采用酶联免疫吸附法和放射免疫法测定 6 0例 CHF患者 (CHF组 )及 2 0例健康人 (正常对照组 )血清 s ICAM- 1及血浆 Ang 水平 ,进行比较和相关分析。结果　 CHF组血清 s ICAM-1及血浆 Ang 水平均较正常对照组明显增高 (P<0 .0 1) ,其增高程度与心功能状态有关。血清 s ICAM- 1与血浆Ang 水平呈正相关 (r=0 .4 91,P<0 .0 1)。结论　 CHF患者血清 s ICAM- 1和血浆 Ang 均增加 ,两者共同作用促进 CHF的发生和发展。     

细胞间黏附分子-1和P-选择素的表达与非小细胞肺癌关系的研究

目的探讨细胞间黏附分子-1(ICAM-1)和P-选择素在肺癌转移机制中的作用。方法采用免疫组化SP法对52例原发性肺癌组织的ICAM-1及P-选择素的表达进行检测。结果(1)肺癌的ICAM-1和P-选择素阳性表达明显高于癌旁组织;(2)ICAM-1及P-选择素在腺癌组织中的阳性表达率显著高于鳞癌,两者在Ⅲ Ⅳ期患者的阳性表达明显高于Ⅰ Ⅱ期;(3)肺癌中有淋巴结转移的ICAM-1的阳性表达率显著高于无淋巴结转移,而P-选择素的表达与淋巴结转移无明显相关性。结论ICAM-1和P-选择素可能与肺癌的浸润转移有关。     

Soluble CD4 and CD8 molecules in patients with systemic sclerosis

Summary The concentrations of sCD4 and sCD8 in 69 patients with systemic sclerosis (SSc) were examined by using a sandwich enzyme-linked immunosorbent assay. The patients with SSc had significantly higher concentrations of sCD8 (mean 249.2 U/ml (SD 155.1), median 224 U/ml) than the normal subjects (mean 149.3 U/ml (SD 42.1), median 148 U/ml). The concentration of sCD4 in patients with SSc were significantly lower (mean 6.2 U/ml (SD 3.8), median 5.0 U/ml) than in the normal subjects (mean 10.9 U/ml (SD 4.1), median 10.3 U/ml). The concentration of sCD8 in patients with diffuse sclerosis tended to be higher than in those with sclerodactyly.     

可溶性Fas,可溶性Fas配体与细胞因子在1型糖尿病发病中的意义

目的　研究可溶性Fas(sFas)和可溶性Fas配体(sFasL)与细胞因子在1型糖尿病发病中的作用。方法　32名1型糖尿病患者和20名正常人的血清,采用夹心BAS-ELISA法分别检测sFas,sFasL,γ干扰素(IFN-γ)及白细胞介素-1(IL-1)含量。结果　1型糖尿病血清中sFas,IFN-γ及IL-1含量分别为(1　　546±685,1　　074±451与1　　406±721)ng/L,显著高于正常组;sFasL为(211±73)mg/L,低于正常组但差异无显著性。在1型糖尿病患者中高浓度sFas伴高IFN-γ者共12例,低浓度sFas伴低IFN-γ者共9例。结论　1型糖尿病患者血清中的sFas,IFN-γ及IL-1高于正常人,sFas与IFN-γ浓度呈正相关(r=0.79,P＜0.05)。对1型糖尿病患者血清进行sFas,IFN-γ及IL-1等检测可作为反映胰岛细胞病变的辅助指标,有助于对疾病的诊断与治疗。     

狼疮肾炎患者血清sFas和sFasL的变化

目的　研究狼疮肾炎患者血清sFas和sFasL的变化及意义。方法　采用双抗体夹心酶联免疫吸附法 (ELISA)检测正常对照 18例和狼疮肾炎患者 45例血清sFas和sFasL水平。结果　狼疮肾炎患者sFas和sFasL水平分别为 (14± 7) μg/L和 (0 0 7± 0 0 4) μg/L ,与正常对照组 (2 9±1 2 ) μg/L和 (0 0 5± 0 0 1) μg/L相比 ,差异有高度显著性意义 (P <0 0 1)。活动期sFas水平较缓解期明显增高 ,分别是 (17± 7) μg/L和 (9± 4) μg/L ,P <0 0 1;但sFasL活动期与缓解期差异无显著意义。狼疮肾炎血清sFas水平在白细胞减少、贫血、大量蛋白尿、肾功能减退、补体降低、ANA和抗RNP Ab阳性时升高 ;而sFasL仅在肾功能异常时减低 ,与其他指标没有明显相关性。结论　sFas及sFasL参与了狼疮肾炎的发生 ,sFas可作为狼疮肾炎的活动性实验室指标。     

血清sFas、sFasL水平与特发性血小板减少性紫癜的关系

采用酶联免疫夹心法(ELISA)检测了25例特发性血小板减少性紫癜(ITP)患者血清中sFas、sFasL的水平.结果显示ITP患者血清sFas含量为16.51±6.86μg/L,sFasL含量为0.48±0.33μg/L,均显著高于正常对照(分别为P<0.001和P<0.01);18例ITP患者血清sFas水平升高,其中有9例同时有sFasL水平升高,但是血清sFas水平升高组的血小板计数与sFas正常组无显著差异.提示sFas和sFasL的异常参与了ITP的免疫病理过程.     

慢性心力衰竭患者的血清可溶性Fas配体和可溶性Fas受体

目的 分析血清可溶性Fas配体(sFasL)和可溶性Fas受体(sEas)与慢性心力衰竭(CHF)的相关性。方法采用酶联免疫吸附双抗体夹心法检测33例CHF患者(CHF组,心功能Ⅱ-Ⅳ级,NYHA)血清sFasL和sFas浓度,并与18例心功能Ⅰ级(NYHA)组比较。结果 CHF与心功能Ⅰ级间sFasL浓度无显著统计学差异[231.50±84.50(心功能Ⅱ级216.50±96.00,Ⅲ级226.80±85.70,Ⅳ级244.00±73.00)vs217.50±89.00pg/mL,P>0.05]。而CHF组血清sFas浓度显著高于心功能Ⅰ级组[1353.30±507.71(心功能Ⅱ级1154.85±371.20,Ⅲ级1412.88±493.62,Ⅳ级1875.67±806.10)vs983.11±461.26pg/mL,P<0.05]。结论 血清sFasL与CHF无相关性。而血清sFas与CHF存在显著相关性。且sFas浓度增高的程度与CHF的严重程度相平行,sFas浓度增高可能在CHF发病机制中起重要作用。     

Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course

Summary Systemic lupus erythematosus (SLE) patients are characterized by a low lymphocyte count, which is considered a specific disease marker and is related to disease activity. The membrane bound molecules CD25 and CD27 are expressed and released in a soluble CD25 (sCD25) and soluble CD27 (sCD27) form by activation of predominantly T cells. In previous studies it was claimed that sCD25 as well sCD27 might be used as parameters for activation of the immune system; a correlation between the sCD25 profile with the disease course in SLE patients was also shown.To assess the relationship between lymphocyte count and these T cell activation markers, we performed a cross-sectional and a longitudinal study. In the longitudinal study three SLE patients who were known for a long time at our outpatient clinic were studied. Both T cell markers strongly correlated with each other and formed a reflection of the disease course. In all 7 periods of exacerbation, which we observed in the 3 investigated patients, both levels increased preceding this period; however, no correlation was found with the lymphocyte count. In the cross sectional study of 69 patients with SLE, sCD25 and sCD27 levels were correlated with defined disease manifestations; sCD25 was elevated in all periods of increased disease activity. The same holds true for sCD27, with the exception of patients with nephritis in which the highest levels were observed. Both profiles of sCD25 and sCD27 were strongly correlated during the whole disease course. Our data prove that in the pathogenesis of SLE an active recruitement of unprimed and primed T cells takes place.     

Effect of disease activity and corticosteroids on serum levels of soluble endothelial cell protein C receptor in patients with systemic lupus erythematosus

To assess the effects of disease activity of systemic lupus erythematosus (SLE) and high-dose corticosteroids on endothelial injuries, the significance of soluble endothelial cell protein C receptor (sEPCR) and soluble thrombomodulin (sTM) was analyzed. Serum levels of sEPCR and sTM were measured by enzyme-linked immunosorbent assay (ELISA) cross-sectionally in 97 SLE patients, 49 patients with other rheumatic diseases and 22 normal subjects. The changes in these levels upon corticosteroid treatment were also analyzed in 41 patients. The levels of sEPCR and sTM were both higher in SLE and other rheumatic disease patients than in normal subjects. When low-dose corticosteroids were used, both the level of sEPCR and the ratio of positive tests for sEPCR were significantly higher in active SLE patients than in inactive patients [median 2.30 ng/ml (range 0.00–147.10 ng/ml) vs 0.00 ng/ml (0.00–58.90 ng/ml) and 53.5 vs 13.0%, respectively] (P < 0.005). Moreover, the ratio of positive tests for sEPCR was higher after corticosteroid treatment in 9 of 19 (47.3%) SLE patients compared to other rheumatic diseases (3/22; 13.6%). Although the mean level of sTM was significantly higher in active SLE patients than in inactive patients, the ratio of positive tests for sTM was not affected by disease activity or corticosteroids. In conclusion, the positive test for sEPCR is a more sensitive biomarker than that for sTM in reflecting endothelial injuries caused by active disease and often by corticosteroids in SLE.     

急性冠状动脉综合征病人血清可溶性Fas和可溶性Fas配体及可溶性白细胞介素2受体水平的临床价值

目的 :探讨血清可溶性Fas、可溶性Fas配体和可溶性白细胞介素 2受体水平与急性冠状动脉综合征 (ACS)之间的关系。方法 :应用酶联免疫吸附双抗体夹心 (ELISA)方法 ,测定了 3 5例ACS病人 (ACS组 )、2 3例稳定性心绞痛病人 (SAP组 )及 2 0例对照组受试者的血清可溶性Fas、可溶性Fas配体和可溶性白细胞介素 2受体水平。结果 :血清可溶性Fas和可溶性白细胞介素 2受体平均水平 ,ACS组明显高于SAP组和对照组 ,有显著性统计学差异 (P <0 0 1) ,而后两组比较无显著性差异 (P >0 0 5 )。 3组间血清可溶性Fas配体平均水平无显著性差异 (P >0 0 5 )。ACS组血清可溶性Fas水平与可溶性白细胞介素 2受体水平存在显著正相关 (γ =0 45 7,P <0 0 1)。结论 :研究表明ACS病人血清可溶性Fas、可溶性白细胞介素 2受体水平明显升高 ,提示其可能与ACS有关。血清可溶性Fas可能通过维持自身免疫炎性反应而导致ACS的发生发展。     

Soluble CD4, CD8 in patients with polymyositis/dermatomyositis

Summary The concentrations of soluble CD4 (sCD4) and soluble CD8 (sCD8) were determined in 64 patients with polymyositis/dermatomyositis (PM/DM). The patients with PM/DM had significantly higher concentrations of sCD8, though the concentrations of sCD4 did not significantly increase. Patients with high concentrations of sCD8 tended to have too high concentrations of soluble interleukin-2 receptor (sIL-2R). The patients with high levels of myogenic enzymes tended to have high concentrations of sCD8. The results of a serial study indicated that the concentrations of sCD8 decreased simultaneously with the decrease of the myogenic enzymes. These results may suggest that the activation of CD8⁺ cells are related to muscular involvement.